To MBA or not to MBA: is that the question?

shells-1193518-640x480

There are many types of leaders, many ways to lead.

“What kind of CEO do you want to be?” That question still rings in my head.

It came after a meeting with a CEO that I’d attended with my dad, one in a string of meetings to match small biotech and health tech companies with potential investors.

My dad, an investor, was letting me flex some muscle. I had hopped straight from earning a PhD in biomedical engineering to consulting at McKinsey – and now, I knew just the questions to ask: if it was a cell therapy or biologic, I’d hammer them on manufacturing or the regulatory process. If it were a device, I’d ask about IP or competition.

Over time, I noticed a pattern in the answers. If the CEO were, say, an MD, he or she would demonstrate less fluency with the financials. And if it were a lawyer at the helm, I’d note the micro-stuttering of a person for whom technology was a “second language” – in other words, someone who’d been taught (rather than having developed) the technology’s mechanism of action.

What I was intuiting from those meetings, it turns out, was the weak spot common to any technologically-based venture: the gap between technology and management, between science and business. This is a language barrier as formidable as any other. Like the gaps between other spoken languages, it blocks understanding within biotech companies, impedes their progress, and is difficult to overcome. Indeed, the deeper a company’s chasm, the more reluctant my dad was to invest.

Continue reading

First Rounders: David Baltimore

Baltimore2

 

The First Rounders podcast with David Baltimore is located here. Here is his lab page at Caltech. Find The New York Times article on his winning the Nobel prize at this link. His page on the Nobel site is here. The New Yorker article covering the charges against the Thereza Imanishi-Kari paper, which we discussed on the podcast, is here (subscription required for full article, though someone has scanned in the PDF). A Nature article on the Asilomar conference found at this link. An interview on PBS concerning AIDS research is here.

Brady Huggett

Guidelines for algorithms and software at Nature Biotechnology

NBT logo red

Nature Biotechnology outlined its recommendations for material sharing and reporting for algorithms and software in a April 2015 Editorial. On this page, the editors provide more detailed information for authors submitting manuscripts containing unpublished algorithms and software.

Client-side Software
This is software that is installed and used on a personal computer and not intended to be accessed remotely as a web service. It can be entirely stand-alone on a commonly available operating system (Windows, Mac OS X, or *nix) or can require the user to have a popular software platform installed (MATLAB or LabVIEW). In all cases, but particularly when using MATLAB or LabVIEW, all platform versions and software dependencies must be detailed in the supplied documentation.

At Submission

  • If the custom algorithm/software is central to the method and has not been reported previously in a published research paper it must be supplied by the authors in a usable form including one or more of the following.
    1. Source code
    2. Complete pseudocode
    3. Full mathematical description of the algorithm
    4. Compiled standalone software

Continue reading